Cargando…

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation

Mostrar otras versiones (2)

Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States Government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different validated pseudovirus-based SARS-CoV-2 neutralization assays, wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yunda, Borisov, Oleg, Kee, Jia Jin, Carpp, Lindsay N., Wrin, Terri, Cai, Suqin, Sarzotti-Kelsoe, Marcella, McDanal, Charlene, Eaton, Amanda, Pajon, Rolando, Hural, John, Posavad, Christine M., Gill, Katherine, Karuna, Shelly, Corey, Lawrence, McElrath, M. Juliana, Gilbert, Peter B., Petropoulos, Christos J., Montefiori, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452111/ https://www.ncbi.nlm.nih.gov/pubmed/34545372 http://dx.doi.org/10.1101/2021.09.09.21263049

Ejemplares similares

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
por: Huang, Ying, et al.
Publicado: (2023)

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research
por: Williamson, Brian D., et al.
Publicado: (2023)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
por: Espy, Nicole, et al.
Publicado: (2023)

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
por: Anderson, Evan, et al.
Publicado: (2022)

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
por: Benkeser, David, et al.
Publicado: (2023)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

A high-throughput SARS-CoV-2 pseudovirus multiplex neutralization assay
por: Sievers, Benjamin Louis, et al.
Publicado: (2022)

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
por: Fong, Youyi, et al.
Publicado: (2018)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Emergent Electroweak Gravity
por: McElrath, Bob
Publicado: (2008)

Laboratory tests for the cosmic neutrino background using beta-decaying nuclei
por: McElrath, Bob
Publicado: (2009)

On The Origin of Neutrino Mass and Mixing in the Standard Model
por: McElrath, Bob
Publicado: (2009)

International Technology Transfer of a GCLP-Compliant HIV-1 Neutralizing Antibody Assay for Human Clinical Trials
por: Ozaki, Daniel A., et al.
Publicado: (2012)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials
por: Sarzotti-Kelsoe, M, et al.
Publicado: (2009)

The Inner Foreskin of Healthy Males at Risk of HIV Infection Harbors Epithelial CD4+ CCR5+ Cells and Has Features of an Inflamed Epidermal Barrier
por: Lemos, Maria P., et al.
Publicado: (2014)

$h \to \mu^{+}\mu^{-}$ via Gluon Fusion at the LHC
por: Han, T, et al.
Publicado: (2002)

Pseudoviruses for the assessment of coronavirus disinfection by ozone
por: Zucker, Ines, et al.
Publicado: (2021)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
por: Seaton, Kelly E., et al.
Publicado: (2023)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

In Men at Risk of HIV Infection, IgM, IgG1, IgG3 and IgA Reach the Human Foreskin Epidermis
por: Lemos, Maria P., et al.
Publicado: (2015)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study
por: Huang, Yunda, et al.
Publicado: (2014)

There is no explosion risk associated with superfluid Helium in the LHC cooling system
por: Fairbairn, Malcolm, et al.
Publicado: (2008)

Validation of an automated system for aliquoting of HIV-1 Env-pseudotyped virus stocks
por: Schultz, Anke, et al.
Publicado: (2018)

P15-04. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells
por: Todd, CA, et al.
Publicado: (2009)

Profiles of Human Serum Antibody Responses Elicited by Three Leading HIV Vaccines Focusing on the Induction of Env-Specific Antibodies
por: Vaine, Michael, et al.
Publicado: (2010)

Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials
por: Sarzotti-Kelsoe, Marcella, et al.
Publicado: (2009)

Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies
por: Bharadwaj, Pranay, et al.
Publicado: (2020)

Signatures of Extra Dimensions from Upsilon Decays with a Light Gaugephobic Higgs Boson
por: Galloway, Jamison, et al.
Publicado: (2008)

HIV-1 pseudoviruses constructed in China regulatory laboratory
por: Nie, Jianhui, et al.
Publicado: (2019)

Teicoplanin inhibits Ebola pseudovirus infection in cell culture
por: Wang, Yizhuo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lsavavfju4ntpc82hs8mqfq2d6